{"organizations": [], "uuid": "53f16bd64cfc6e56bff7b284f1cf5263b700f23b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/02/globe-newswire-inspire-medical-systems-inc-announces-pricing-of-initial-public-offering.html", "country": "US", "domain_rank": 767, "title": "Inspire Medical Systems, Inc. Announces Pricing of Initial Public Offering", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T01:00:00.000+03:00", "replies_count": 0, "uuid": "53f16bd64cfc6e56bff7b284f1cf5263b700f23b"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/02/globe-newswire-inspire-medical-systems-inc-announces-pricing-of-initial-public-offering.html", "ord_in_thread": 0, "title": "Inspire Medical Systems, Inc. Announces Pricing of Initial Public Offering", "locations": [], "entities": {"persons": [{"name": "stifel", "sentiment": "none"}], "locations": [{"name": "minneapolis", "sentiment": "none"}], "organizations": [{"name": "nyse", "sentiment": "negative"}, {"name": "inspire medical systems, inc", "sentiment": "neutral"}, {"name": "new york stock exchange", "sentiment": "none"}, {"name": "llc", "sentiment": "none"}, {"name": "guggenheim securities", "sentiment": "none"}, {"name": "goldman sachs & co", "sentiment": "none"}, {"name": "bofa merrill lynch", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MINNEAPOLIS, May 02, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the pricing of its initial public offering of 6,750,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Inspire. In addition, Inspire has granted the underwriters a 30-day option to purchase up to 1,012,500 additional shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on May 3, 2018 under the ticker symbol “INSP.” The offering is expected to close on May 7, 2018, subject to customary closing conditions.\nBofA Merrill Lynch and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Guggenheim Securities, Stifel and Wells Fargo Securities are acting as co-managers for the offering.\nA registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: dg.prospectus_requests@baml.com ; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com .\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Inspire Medical Systems\nInspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.\nInspire Investor and Media Contact\nBob Yedid\nLifeSci Advisors\nbob@lifesciadvisors.com\n646-597-6989\nSource:Inspire Medical Systems, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=CJkTz0CYsXndqJeKkpAKzFMP1nBH5jNy7G476k5DkULBk4EwYNxV8ZGEZA_cvnniZALC4nGFpkTgWK7DgrHCsSUphraNeJVImWm2TXk3uyYOWppbVG9HIm0TjROt-HEo", "https://www.globenewswire.com/Tracker?data=e-TBTxJ-5qfYvtBQbxwulB9rcuBaqSnU_m9AFzn_ly0LVYx1MrrgWPDtffvaHiDqidEq0VbgXiGjsYXPX56ADbuLoQ7qf9ePU6OLfk7SVGg=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/b831ded8-0d58-4501-9aee-8263db12c9c3", "https://www.globenewswire.com/Tracker?data=2bV4c6xp8Aq8E2bONhxNeggmI0O8TNwoN0L-T2iV5GJQ5ygrhfjDZADYjFhK033Mhao51R1seiNoJYQz5PEpB3y2ryDou03G7QcF25WY-Yi9J5qNpREPXay4BavBW1jR"], "published": "2018-05-03T01:00:00.000+03:00", "crawled": "2018-05-03T01:53:31.022+03:00", "highlightTitle": ""}